Conferences
ESMO 2023: APEX-01: First-in-Human Phase 1/2 Study of ARX517, an Anti-PSMA ADC, in Patients with mCRPC
October 23, 2023
ESMO 2023: How to Best Integrate Biology
October 23, 2023
ESMO 2023: PSMAfore Phase 3 Trial of [177Lu]Lu-PSMA-617 in Taxane-Naive Patients with Metastatic Castration Resistant Prostate Cancer
October 23, 2023
ESMO 2023: Advances in the Molecular Understanding of GU Cancers: The Next Generation of Therapeutic Targets
October 23, 2023
ESMO 2023: Prediction of Toxicity in Current Systemic Treatment of Genitourinary Cancers
October 23, 2023
ESMO 2023: Discussant: TAR-210 & SunRISe-1
October 23, 2023
ESMO 2023: Discussant – ABACUS-2, NEMIO, EV-103 (Cohort-L)
October 23, 2023